| Immunity, inflammation and cancer: a leading role for adenosine L Antonioli, C Blandizzi, P Pacher, G Haskó Nature Reviews Cancer 13 (12), 842-857, 2013 | 809 | 2013 |
| Effective and safe proton pump inhibitor therapy in acid-related diseases–a position paper addressing benefits and potential harms of acid suppression C Scarpignato, L Gatta, A Zullo, C Blandizzi, ... BMC medicine 14, 1-35, 2016 | 375 | 2016 |
| Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis–an expert consensus addressing benefits as well as gastrointestinal and cardiovascular … C Scarpignato, A Lanas, C Blandizzi, WF Lems, M Hermann, RH Hunt, ... BMC medicine 13, 1-22, 2015 | 295 | 2015 |
| Anti-CD73 in cancer immunotherapy: awakening new opportunities L Antonioli, GG Yegutkin, P Pacher, C Blandizzi, G Haskó Trends in cancer 2 (2), 95-109, 2016 | 237 | 2016 |
| Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? C Pellegrini, L Antonioli, R Colucci, C Blandizzi, M Fornai Acta neuropathologica 136, 345-361, 2018 | 220 | 2018 |
| Canonical and non-canonical activation of NLRP3 inflammasome at the crossroad between immune tolerance and intestinal inflammation C Pellegrini, L Antonioli, G Lopez-Castejon, C Blandizzi, M Fornai Frontiers in immunology 8, 237490, 2017 | 205 | 2017 |
| Hydrogen sulphide: novel opportunity for drug discovery A Martelli, L Testai, MC Breschi, C Blandizzi, A Virdis, S Taddei, ... Medicinal research reviews 32 (6), 1093-1130, 2012 | 188 | 2012 |
| Adenosine and inflammation: what's new on the horizon? L Antonioli, B Csóka, M Fornai, R Colucci, E Kokai, C Blandizzi, G Haskó Drug Discovery Today 19 (8), 1051-1068, 2014 | 187 | 2014 |
| Adenosine signalling in diabetes mellitus—pathophysiology and therapeutic considerations L Antonioli, C Blandizzi, B Csóka, P Pacher, G Haskó Nature reviews endocrinology 11 (4), 228-241, 2015 | 185 | 2015 |
| Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders L Antonioli, R Colucci, C La Motta, M Tuccori, O Awwad, F Da Settimo, ... Current drug targets 13 (6), 842-862, 2012 | 175 | 2012 |
| Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome C Stasi, M Bellini, G Bassotti, C Blandizzi, S Milani Techniques in coloproctology 18, 613-621, 2014 | 172 | 2014 |
| Adenosine signaling and the immune system: When a lot could be too much L Antonioli, M Fornai, C Blandizzi, P Pacher, G Haskó Immunology letters 205, 9-15, 2019 | 166 | 2019 |
| Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease M Cocco, C Pellegrini, H Martínez-Banaclocha, M Giorgis, E Marini, ... Journal of Medicinal Chemistry 60 (9), 3656-3671, 2017 | 147 | 2017 |
| Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation A Virdis, A Bacca, R Colucci, E Duranti, M Fornai, G Materazzi, C Ippolito, ... Hypertension 62 (2), 337-344, 2013 | 143 | 2013 |
| Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline M Tuccori, S Ferraro, I Convertino, E Cappello, G Valdiserra, C Blandizzi, ... MAbs 12 (1), 1854149, 2020 | 142 | 2020 |
| Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review M Tuccori, A Testi, L Antonioli, M Fornai, S Montagnani, N Ghisu, ... Clinical therapeutics 31, 1426-1453, 2009 | 141 | 2009 |
| molecular, pathological and therapeutic features of human enteric neuropathies G DI NARDO, C Blandizzi, U Volta, R Colucci, V Stanghellini, G Barbara, ... Alimentary pharmacology & therapeutics 28 (1), 25-42, 2008 | 137 | 2008 |
| Inhibition of adenosine deaminase attenuates inflammation in experimental colitis L Antonioli, M Fornai, R Colucci, N Ghisu, F Da Settimo, G Natale, ... Journal of Pharmacology and Experimental Therapeutics 322 (2), 435-442, 2007 | 137 | 2007 |
| Vascular generation of tumor necrosis factor-α reduces nitric oxide availability in small arteries from visceral fat of obese patients A Virdis, F Santini, R Colucci, E Duranti, G Salvetti, I Rugani, C Segnani, ... Journal of the American College of Cardiology 58 (3), 238-247, 2011 | 136 | 2011 |
| The purinergic system as a pharmacological target for the treatment of immune-mediated inflammatory diseases L Antonioli, C Blandizzi, P Pacher, G Haskó Pharmacological reviews 71 (3), 345-382, 2019 | 134 | 2019 |
